Core Insights - Alibaba Health reported a revenue of 16.697 billion yuan for the first half of the fiscal year 2026, representing a year-on-year growth of 17% [1] - The company achieved a gross profit of 4.184 billion yuan, up 18.4% year-on-year, and a net profit of 1.266 billion yuan, which is a significant increase of 64.7% [1] - Adjusted net profit reached 1.356 billion yuan, reflecting a growth of 38.7% [1] - The company is committed to investing in the medical AI sector and enhancing its strategic layout in the B2B medical vertical [1] Business Performance - Alibaba Health is the largest online B2C healthcare product retail platform in China, with over 56,000 active merchants and an increase of over 97 million SKUs [1] - The platform's annual active user count and annualized ARPU continue to grow, with GMV showing stable high-quality growth [1] - The self-operated pharmacy business generated revenue of 14.38 billion yuan, marking an 18.6% increase, with a 98.8% year-on-year growth in SKUs to 1.61 million [1] Strategic Collaborations - Alibaba Health has deepened partnerships with major pharmaceutical companies, launching dozens of new specialty drugs and providing comprehensive services from drug listing to patient education and delivery [2] - Collaborations with leading firms such as Eli Lilly, AstraZeneca, and Pfizer focus on digital health services, expanding the outpatient market for pharmaceutical partners [2] Integrated Health Services - The company offers integrated online and offline healthcare services, with over 250,000 licensed healthcare professionals providing online consultation services [2] - Alibaba Health's internet hospital continues to serve chronic disease patients, with user numbers and ARPU showing consistent growth [2] Traditional Chinese Medicine (TCM) Services - The TCM service segment is experiencing stable growth, with the establishment of a self-operated TCM dispensing center network across several provinces [3] - The company has over 150,000 registered TCM practitioners, enhancing its medical service network [3] Digital Infrastructure and AI Development - The "Code on Trust" platform provides free traceability services to 560,000 pharmaceutical enterprises, expanding its reach into medical devices and traditional Chinese medicine [3] - Alibaba Health collaborates with over 900 leading pharmaceutical companies to provide data analysis services [3] - The company is increasing investments in medical AI, aiming to improve user experience and explore applications in serious medical fields [3]
阿里健康发布2026财年中期业绩:净利润同比增长64.7%